TY - JOUR T1 - Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. JF - Nat Commun Y1 - 2019 A1 - Menden, Michael P A1 - Wang, Dennis A1 - Mason, Mike J A1 - Szalai, Bence A1 - Bulusu, Krishna C A1 - Guan, Yuanfang A1 - Yu, Thomas A1 - Kang, Jaewoo A1 - Jeon, Minji A1 - Wolfinger, Russ A1 - Nguyen, Tin A1 - Zaslavskiy, Mikhail A1 - Jang, In Sock A1 - Ghazoui, Zara A1 - Ahsen, Mehmet Eren A1 - Vogel, Robert A1 - Neto, Elias Chaibub A1 - Norman, Thea A1 - Tang, Eric K Y A1 - Garnett, Mathew J A1 - Veroli, Giovanni Y Di A1 - Fawell, Stephen A1 - Stolovitzky, Gustavo A1 - Guinney, Justin A1 - Dry, Jonathan R A1 - Saez-Rodriguez, Julio KW - ADAM17 Protein KW - Antineoplastic Combined Chemotherapy Protocols KW - Benchmarking KW - Biomarkers, Tumor KW - Cell Line, Tumor KW - Computational Biology KW - Datasets as Topic KW - Drug Antagonism KW - Drug Resistance, Neoplasm KW - Drug Synergism KW - Genomics KW - Humans KW - Molecular Targeted Therapy KW - mutation KW - Neoplasms KW - pharmacogenetics KW - Phosphatidylinositol 3-Kinases KW - Phosphoinositide-3 Kinase Inhibitors KW - Treatment Outcome AB -

The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.

VL - 10 IS - 1 U1 - https://www.ncbi.nlm.nih.gov/pubmed/31209238?dopt=Abstract ER - TY - JOUR T1 - Prediction of human population responses to toxic compounds by a collaborative competition. JF - Nature biotechnology Y1 - 2015 A1 - Eduati, Federica A1 - Mangravite, Lara M A1 - Wang, Tao A1 - Tang, Hao A1 - Bare, J Christopher A1 - Huang, Ruili A1 - Norman, Thea A1 - Kellen, Mike A1 - Menden, Michael P A1 - Yang, Jichen A1 - Zhan, Xiaowei A1 - Zhong, Rui A1 - Xiao, Guanghua A1 - Xia, Menghang A1 - Abdo, Nour A1 - Kosyk, Oksana AB - The ability to computationally predict the effects of toxic compounds on humans could help address the deficiencies of current chemical safety testing. Here, we report the results from a community-based DREAM challenge to predict toxicities of environmental compounds with potential adverse health effects for human populations. We measured the cytotoxicity of 156 compounds in 884 lymphoblastoid cell lines for which genotype and transcriptional data are available as part of the Tox21 1000 Genomes Project. The challenge participants developed algorithms to predict interindividual variability of toxic response from genomic profiles and population-level cytotoxicity data from structural attributes of the compounds. 179 submitted predictions were evaluated against an experimental data set to which participants were blinded. Individual cytotoxicity predictions were better than random, with modest correlations (Pearson’s r < 0.28), consistent with complex trait genomic prediction. In contrast, predictions of population-level response to different compounds were higher (r < 0.66). The results highlight the possibility of predicting health risks associated with unknown compounds, although risk estimation accuracy remains suboptimal. UR - http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.3299.html ER -